Clinical trials: Hepatitis B, completed
Chronic Hepatitis B
A Study of BW-20507 in Chinese Healthy Subjects and Subjects With Chronic Hepatitis B
Phase 1 Study of BW-20507 in Healthy Subjects and Patients With Chronic Hepatitis B. Ia involved a single ascending dose study where healthy participants were administered one dose of BW-20507 or placebo subcutaneously.
- Trial name
- HBV (NCT07595159)
- Testing
- BW-20507
- Where
- 4 sites in China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
Hepatitis B Virus, HIV
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
This is a prospective HIV cohort that aims to establish causes of liver disease among HIV-infected individuals in Zambia, including viral hepatitis and alcohol.
- Conditions
- Hepatitis B Virus, HIV, Antiretroviral Therapy, Africa
- Trial name
- NCT02060162
- Testing
- Standard of care
- Where
- Zambia
- Volunteers
- 897 people
- Sponsor
- University of Alabama at Birmingham
Hepatitis B, Chronic
Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA
This is a randomized, open-labelled, prospective 96-week study comparing the antiviral efficacy and safety of switching to entecavir 1 mg QD from lamivudine versus maintaining lamivudine 100 mg QD treatment in HBV-infected…
- Trial name
- NCT00625560
- Testing
- Entecavir, Lamivudine
- Where
- 2 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Yonsei University
Hepatitis B, Chronic
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants
The purpose of this study is to evaluate efficacy of the study intervention, based on hepatitis B surface antigen (HBsAg) levels at follow-up (FU) Week 24.
- Trial name
- OCTOPUS-1 (NCT05275023)
- Testing
- JNJ-73763989, PD-1 inhibitor, Tenofovir Disoproxil
- Where
- 26 sites in Canada, Czechia and 6 more
- Volunteers
- 37 people
- Sponsor
- Janssen Research & Development, LLC
Hepatitis B, Hepatitis C
Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV
In this study, researchers from UCLA and Friends Community Center will work together in designing a program to assist young homeless stimulant-using gay and bisexual homeless men to complete the hepatitis vaccine and in reducing…
- Conditions
- Hepatitis B, Hepatitis C, HIV, HIV Infections
- Trial name
- HBV (NCT00926146)
- Testing
- NCMIT, SCMIT
- Where
- United States
- Volunteers
- 451 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Liver Diseases, Hepatitis, Chronic
Epidemiological Study in Children and Adolescents With Chronic Hepatitis B
The purpose of this study is to collect epidemiological data in children and adolescents with chronic hepatitis B(CHB), in particular data on the prevalence of HBeAg positive disease with associated ALT levels , active HBeAg…
- Conditions
- Liver Diseases, Hepatitis, Chronic, Hepatitis, Viral, Human, Hepatitis
- Trial name
- EPIC B (NCT01163240)
- Where
- 86 sites in United States, Argentina and 16 more
- Volunteers
- 1,640 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).
This 4 arm study will compare the efficacy and safety of PEGASYS given for 24 or 48 weeks, and at doses of 90 or 180 micrograms weekly, in the treatment of HBeAg positive patients with chronic hepatitis B.
- Trial name
- NCT00435825
- Testing
- peginterferon alfa-2a [Pegasys]
- Where
- 55 sites in United States, Australia and 11 more
- Volunteers
- 551 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
Evaluate the Efficacy and Safety to Tenofovir Disoproxil in Chronic Hepatitis B Patients
This study evaluates the efficacy and safety of switching to Tenofovir Disoproxil from Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients who pretreated with Tenofovir Disoproxil Fumarate.
- Trial name
- HBV (NCT03485534)
- Testing
- Tenofovir Disoproxil Fumarate, Tenofovir Disoproxil
- Where
- South Korea
- Volunteers
- 189 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Bacterial Infections, Virus Diseases
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
This study will determine whether participants who receive V419 (PR5I) at 2, 4, and 11 to 12 months of age have an acceptable response to the vaccine.
- Trial name
- NCT01480258
- Testing
- PR5I, Rotavirus vaccine, Prevenar 13™
- Volunteers
- 1,315 people, healthy volunteers welcome
- Sponsor
- MCM Vaccines B.V.
Chronic Hepatitis B
A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection
The objectives of this study are to demonstrate that entecavir has antiviral activity with undetectable at Week 48, and to assess the safety and the pharmacokinetic in Japanese patients given entecavir at each dose of 0.1 and 0.5…
- Trial name
- NCT01020565
- Testing
- Entecavir
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, Cirrhosis
Prevention of Recurrent Hepatitis B After Liver Transplantation
Hepatitis B accounts for approximately 5000 deaths per year in the United States. Liver transplantation offers the only hope for patients who develop end-stage liver disease.
- Conditions
- Hepatitis B, Cirrhosis, Acute Liver Failure, Hepatocellular Carcinoma
- Trial name
- NCT00059267
- Testing
- HBIG, Epivir, Hepsera
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis B Infection
Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh.
Hepatitis B is a common and serious infectious disease of the liver, affecting millions of people throughout the world. Persistent Hepatitis B virus infections may cause development of chronic hepatic insufficiency, cirrhosis and…
- Trial name
- NCT03627507
- Testing
- Hepa-B, Engerix B
- Where
- Bangladesh
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Meningococcal Disease, Meningococcal Meningitis
Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine
This study compares the safety and immunogenicity profile of combined hepatitis A/B vaccine given alone or concomitantly with MenACWY-CRM to healthy adults.
- Conditions
- Meningococcal Disease, Meningococcal Meningitis, Hepatitis A, Hepatitis B
- Trial name
- NCT01453348
- Testing
- MenACWY-CRM, Combined inactivated hepatitis A & recombinant hepatitis B, Recombinant hepatitis B vaccine
- Where
- 4 sites in Germany
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Chronic Hepatitis B
Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment
Background: Chronic hepatitis B is caused by a virus that infects the liver. Cure is not possible but the virus can be controlled with the use of antiviral medicines,.
- Trial name
- NCT02364336
- Testing
- Peginterferon alfa-2a
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis b
This is a Phase 1 Study in Which Healthy Volunteers and Participants With Chronic HBV Infection Will be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity
Phase 1 Study of HT-101 in Healthy Subjects and Patients With Chronic Hepatitis B The trial consisted of two components. Part A involved a single ascending dose study where healthy participants were administered one dose of…
- Trial name
- NCT06746311
- Testing
- HT-101
- Where
- 7 sites in China
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Suzhou HepaThera Biotech Co., Ltd.
Hepatitis B, Chronic
A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive
This open-label, multi-center study will evaluate the effect on the quantitative HBsAg reduction of peginterferon alfa-2a [PEGASYS] in patients with HBeAg positive chronic hepatitis B.
- Trial name
- NCT01086085
- Testing
- Adefovir, peginterferon alfa-2a [PEGASYS]
- Where
- 11 sites in China
- Volunteers
- 265 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B
This trial is to assess the efficacy and safety of Polyethylene Glycol thymosin alpha1 (PEG-Tα1), a new long immunomodulator (Category 1.1 of Chemical Drugs) being developed from Hansoh Pharmaceutical of China, in combination…
- Trial name
- PEG-Tα1 (NCT02366208)
- Testing
- PEG-Tα1, Adefovir
- Where
- 12 sites in China
- Volunteers
- 116 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Hepatitis C
Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure
The purpose of this study is to describe the management of patients with chronic hepatitis C and previous treatment failure.
- Trial name
- NCT01033045
- Where
- 104 sites in Spain
- Volunteers
- 2,178 people
- Sponsor
- Fundacion IMIM
Opioid-use Disorder, HIV Infections
Project MATLINK: Development and Evaluation of a Screening, Brief Intervention, & Referral to Treatment (SBIRT) Program for Opioid Dependent Prisoners and Probationers Transitioning to the Community
The purpose of this study is to evaluate the efficacy a Screening, Brief Intervention, and Referral to Treatment (SBIRT) program for linking opioid dependent individuals currently incarcerated or in probation in Moldova…
- Conditions
- Opioid-use Disorder, HIV Infections, Tuberculosis, Hepatitis C
- Trial name
- MATLINK (NCT04947475)
- Testing
- SBIRT
- Where
- 3 sites in Kyrgyzstan, Moldova and 1 more
- Volunteers
- 835 people
- Sponsor
- Yale University
Hepatitis B, Chronic
An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons (kD) (PEGASYS) - The PRO B Study
This open--label, multicenter, national observational study will investigate the effectiveness of standard of care treatment with peginterferon alfa-2a in participants with chronic hepatitis B (CHB).
- Trial name
- NCT02201407
- Testing
- Peginterferon alfa-2a
- Where
- 6 sites in Serbia
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.